Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Other operating expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Danaher

Danaher Corp. operates as a medical company, which designs, manufactures, and markets professional, medical, industrial, and commercial products and services. It operates through the following segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, to understand the causes of disease, identify new therapies and test new drugs and vaccines. The Diagnostics segment is composed of analytical instruments, reagents, consumables, software, and services that hospitals, physicians' offices, reference laboratories, and other critical care settings use to diagnose disease and make treatment decisions. The Environmental & Applied Solution segment offers products and services that help protect important resources and keep global food and water supplies safe. The company was founded by Steven M. Rales and Mitchell P. Rales in 1984 and is headquartered in Washington, DC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Danaher exceeds Q1 expectations, eyes growth in China market

Danaher's Q1 performance showcased resilience and strategic focus amidst revenue challenges.
The company's strengths in operational efficiency and strategic initiatives position it well for future growth.
Challenges in certain segments highlight the need for adaptive strategies and market diversification.
Opportunities in China's market recovery and operational improvements offer avenues for sustained growth.

Danaher reports resilient Q2 performance amid COVID-19 challenges

Danaher navigated Q2 2023 with resilience amidst COVID-19 challenges, showcasing strong financial performance and strategic focus. While facing revenue declines in certain segments, the company remains confident in its ability to create shareholder value and improve human health. Capital deployment, inventory management, and market alignment present opportunities for future growth.

Danaher reports Q3 revenue decline, eyes growth in diagnostics market

Danaher's Q3 performance showed revenue declines in key segments, but strategic moves like spin-offs and acquisitions indicate a focus on long-term growth. Challenges in China and revenue projections for the year present short-term hurdles, while opportunities in drug development and diagnostics offer potential for future expansion.

Danaher reports solid 2023 performance, anticipates gradual growth in 2024

Danaher Corporation's 2023 performance showcased strong full-year sales and operating profit margin, but the fourth quarter saw a decline in core revenue. The company is focused on enhancing its portfolio and strengthening its growth trajectory, with expectations for improved growth in the second half of 2024. Challenges include the need for gradual improvement in demand and the pace of recovery in different geographies.

Danaher beats Q1 expectations, eyes growth in Diagnostics segment

Danaher's Q1 2024 performance exceeded expectations, driven by strong Diagnostics segment growth.
While facing challenges in bioprocessing and margin expectations, the company remains focused on long-term sustainability.
Opportunities lie in anticipated growth in Diagnostics and bioprocessing segments, with a focus on innovation and recurring revenue.
Continuous monitoring of market trends and global capabilities position Danaher for future success.

Danaher beats Q2 expectations, eyes growth amid revenue challenges

Danaher Corporation delivered a strong performance in Q2 2024, surpassing revenue, earnings, and cash flow expectations, driven by bioprocessing and Cepheid's success.
While facing challenges such as core revenue declines in the biotechnology segment, the company maintains a solid financial position with strong free cash flow.
Opportunities lie in leveraging positive momentum in key segments, expanding market share, and enhancing sustainability efforts to drive future growth and profitability.
Overall, Danaher's strategic focus on operational efficiency and growth areas positions it well to navigate challenges and capitalize on opportunities in the evolving market landscape.

Danaher surpasses Q3 expectations, eyes China stimulus for growth

Danaher's Q3 performance exceeded expectations, driven by strong results in biotechnology and Cepheid's core revenue growth.
While facing challenges in China market dynamics and core revenue declines in certain segments, the company remains optimistic about future growth.
Opportunities lie in leveraging China's stimulus for 2025 outlook and strategic M&A activities to fuel long-term growth and innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Danaher Corp. engages in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services. It operates through the following segments: Biotechnology, Life Sciences, Diagnostics, and Environmental and Applied Solutions. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a range of tools, consumables, and services. The Life Sciences segment offers a range of instruments and consumables to study the basic building blocks of life, including DNA and RNA. The Diagnostics segment offers clinical instruments, reagents, consumables, software, and services used to diagnose disease and make treatment decisions. The Environmental and Applied Solution segment offers products and services that help protect important resources and keep global food and water supplies safe. The company was founded by Steven M. Rales and Mitchell P. Rales in 1984 and is headquartered in Washington, DC.

The healthcare-focused company continues to power higher. Here's what's driving it, and why the stock can continue to appreciate.

Should You Buy Danaher Stock at Its All-Time High?

Danaher (DHR) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Earnings Estimates Rising for Danaher (DHR): Will It Gain?

Does Danaher (DHR) have what it takes to be a top stock pick for momentum investors? Let's find out.

Here's Why Danaher (DHR) is a Great Momentum Stock to Buy

Danaher Corporation (DHR) CEO Tom Joyce on Q2 2020 Results - Earnings Call Transcript

Danaher's (DHR) Q2 results gain from contribution from Cytiva and suffer from forex woes. Core sales in Q3 are expected to grow primarily on gains from Cytiva.

Danaher (DHR) Beats on Q2 Earnings, Gives Impressive View

Roche Holding AG

Revenue from coronavirus tests helped bolster Roche and Danaher's second quarters, but the health care stocks diverged Thursday. Roche also reported a big decline in pharmaceutical sales.

Covid Report: Why These Health Stocks Diverged On Strong Testing Sales

Danaher (DHR) delivered earnings and revenue surprises of 35.85% and 6.74%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Danaher (DHR) Q2 Earnings and Revenues Surpass Estimates

Shares of Danaher (NYSE:DHR) moved higher by 2.1% in pre-market trading after the company reported Q2 results.

Danaher: Q2 Earnings Insights

WASHINGTON, July 23, 2020 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the quarter ended July 3, 2020. All results in this release reflect only continuing operations unless otherwise noted.

Danaher Reports Second Quarter 2020 Results

AutoNation

CoreLogic

NextEra Energy

Despite this gloomy scenario, there are a handful of stocks with a favorable Zacks Rank set to beat on earnings estimates this week.

4 Must-Buy Stocks Poised to Beat on Q2 Earnings This Week

Danaher (DHR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Danaher (DHR) Upgraded to Buy: What Does It Mean for the Stock?

Danaher's (DHR) Q2 results are anticipated to reflect healthy demand for some of its products and synergistic gains from Cytiva. Yet, subdued demand for a few other products is expected to have ailed.

Will Danaher (DHR) Keep Its Earnings Streak Alive in Q2?

Danaher (DHR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Danaher (DHR) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Danaher (DHR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for Danaher (DHR) This Earnings Season?

WASHINGTON, July 13, 2020 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that it will webcast its quarterly earnings conference call for the second quarter 2020 on Thursday, July 23, 2020 beginning at 8:00 a.m. ET and lasting approximately 1 hour. The call and an...

Danaher Schedules Second Quarter 2020 Earnings Conference Call

Danaher (DHR) Expected to Beat Earnings Estimates: Should You Buy?

Danaher (DHR), with 26% growth in shares in the past three months, benefits from healthy demand for its products and synergistic benefits from acquired assets despite the pandemic-led woes.

Danaher Shares Gain 26% in 3 Months: What's Driving the Rally?

Danaher's Covid-19 antibodies test received emergency clearance from the U.S. Food and Drug Administration, the medical device maker said Monday.

U.S. FDA allows emergency use of Danaher's Covid-19 antibody test

Raytheon Technologies

TPI Composites

Raytheon Technologies, Danaher, and TPI Composites operate in the same end markets as GE and they are arguably better stocks to buy right now.

Ignore General Electric: Here Are 3 Better Stocks

Medtronic

DENTSPLY SIRONA

On 6/25/20, Danaher, DENTSPLY SIRONA and Medtronic will all trade ex-dividend for their respective upcoming dividends.

Ex-Dividend Reminder: Danaher, DENTSPLY SIRONA And Medtronic

Danaher's (DHR) risks from pandemic-related uncertainties are evident from weak sales projections for the second quarter. Demand for acute care diagnostics' related products might aid results.

Danaher's (DHR) Product Offerings to Aid Amid Pandemic Scares

Danaher (DHR) reported earnings 30 days ago. What's next for the stock?

Why Is Danaher (DHR) Up 3.3% Since Last Earnings Report?

Danaher (DHR) completes the offering of common and convertible preferred shares. It intends on using the funds raised to pay for its corporate needs.

Danaher's Stock Offering Proceeds to Fund Corporate Needs

Alexion Pharma

Booking Hlds

Dunkin' Brands

Knowles

Lam Research

Mastercard

MercadoLibre

Ken Fisher (Trades, Portfolio), founder of Fisher Asset Management, bought shares of the following stocks in both the fourth quarter of 2019 and the first quarter of 2020.

8 Stocks Ken Fisher Continues to Buy

Danaher Corporation (DHR) CEO Tom Joyce on Q1 2020 Results - Earnings Call Transcript

News for Danaher Stock (DHR)